手術(shù)和藥物治療兒童腺樣體肥大的臨床療效觀察
發(fā)布時間：2018-10-19 16:26
【摘要】：目的:本次采用隨機對照法研究手術(shù)治療和藥物治療伴有呼吸相關(guān)睡眠障礙癥狀的腺樣體肥大的臨床療效,一方面希望為臨床腺樣體肥大規(guī)范化治療提供參考依據(jù),另一方面通過前瞻性研究藥物治療已有伴隨癥狀的腺樣體肥大的可行性,已期為臨床上推廣保守治療腺樣體肥大提供臨床依據(jù)。方法:實驗研究對象選自我院門診自2016年1月初到2016年12月底臨床上診斷為伴呼吸相關(guān)睡眠障礙癥狀的中、高度腺樣體肥大生病兒童59例(所有研究對象病史均12周)。遵循隨機對照的原則分為三個實驗組,其中A組即手術(shù)組(行氣靜復合麻醉后鼻內(nèi)鏡下腺樣體吸切術(shù))19例,B組即聯(lián)合用藥組(口服孟魯司特鈉+鼻用糠酸莫米松鼻噴劑)20例,C組即單獨藥物組(單一口服孟魯司特鈉)20例,治療時間3個月,比較三組研究對象治療前、后呼吸相關(guān)睡眠障礙癥狀問卷調(diào)查總評分(依據(jù)改良后Bitar評分[1])、電子鼻咽鏡下腺樣體體積好轉(zhuǎn)率,采用計數(shù)資料卡方檢驗,計量資料以均數(shù)±標準差表示,進行t檢驗、卡方檢驗等統(tǒng)計學檢驗,p0.05為差異有統(tǒng)計學意義。結(jié)果:三組治療前呼吸相關(guān)睡眠障礙癥狀總評分差異無統(tǒng)計學意義(F=0.511,P0.05),接受治療3個月后,三組呼吸相關(guān)睡眠障礙癥狀總評分差異有統(tǒng)計學意義(F=21.829,P0.05),A組較B、C組治療后總評分差異均有統(tǒng)計學意義(χ2=10.810,29.476,P0.017),腺樣體體積好轉(zhuǎn)率A組優(yōu)于B、C組。B組與C組治療后總評分差異有統(tǒng)計學意義(χ2=6.465,P0.017),腺樣體體積好轉(zhuǎn)率B組優(yōu)于C組。結(jié)論:手術(shù)治療和藥物治療伴呼吸相關(guān)睡眠障礙癥狀的中、高度腺樣體肥大,均可一定程度緩解生病兒童臨床癥狀,消除不良體征。手術(shù)治療療效最顯著,聯(lián)合藥物治療優(yōu)于單獨藥物治療。針對拒絕早期手術(shù)干預治療的生病兒童,優(yōu)先考慮聯(lián)合藥物保守治療3個月,若改善無效或有癥狀加重情況,仍建議及早接受手術(shù)治療。
[Abstract]:Objective: to study the clinical effect of adenoid hypertrophy with apnea associated sleep disorder by using randomized controlled method, in order to provide reference for the standardized treatment of adenoid hypertrophy. On the other hand, the feasibility of drug therapy for adenoid hypertrophy with symptoms has been studied prospectively, which provides clinical basis for the clinical application of conservative treatment of adenoid hypertrophy. Methods: the subjects of the study were 59 children with high adenoid hypertrophy who were clinically diagnosed as apnea associated sleep disorder from January 2016 to December 2016 (all the subjects' history was 12 weeks). According to the principle of random control, they were divided into three experimental groups. There were 19 cases in group A (adenoidectomy under nasal endoscope after combined anesthesia), 20 cases in group B (oral montelukast sodium for nasal use of amethasone furoate) and 20 cases in group C (single oral drug). 20 patients were treated with montelukast sodium. The duration of treatment was 3 months. The total score of questionnaire (based on improved Bitar score [1]) before and after treatment was compared between the three groups. The improvement rate of adenoid volume under electronic nasopharyngoscope was measured by chi-square test. The measurement data were expressed as mean 鹵standard deviation. T test, chi-square test and other statistical tests were performed, p0.05 was statistically significant. Results: there was no significant difference in the total score of the three groups before treatment (FV 0.511 P 0.05), but after 3 months of treatment, there was no significant difference in the total score of the three groups. There were significant differences in the total scores of respiratory related sleep disorders among the three groups (FF21.829P 0.05) compared with those in group C (P 0.017). The improvement rate of adenoid volume in group A was better than that in group B (P 0.017), and the difference in total score between group B and group C was significant (P < 0.05). The difference was statistically significant (蠂 2, 6.465, P 0.017). The improvement rate of adenoid volume in group B was better than that in group C. Conclusion: the moderate and high adenoid hypertrophy associated with apnea associated sleep disorder in surgical treatment and drug therapy can alleviate the clinical symptoms and eliminate the adverse signs in children with diseases. Surgical treatment is the most effective, combined drug therapy is better than the single drug treatment. For the sick children who refuse early surgical intervention, priority should be given to the combination of medication and conservative treatment for 3 months. If the treatment is ineffective or symptomatic exacerbation, it is still recommended to receive surgical treatment as early as possible.
【學位授予單位】：蚌埠醫(yī)學院
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R766.9
本文編號：2281687
[Abstract]:Objective: to study the clinical effect of adenoid hypertrophy with apnea associated sleep disorder by using randomized controlled method, in order to provide reference for the standardized treatment of adenoid hypertrophy. On the other hand, the feasibility of drug therapy for adenoid hypertrophy with symptoms has been studied prospectively, which provides clinical basis for the clinical application of conservative treatment of adenoid hypertrophy. Methods: the subjects of the study were 59 children with high adenoid hypertrophy who were clinically diagnosed as apnea associated sleep disorder from January 2016 to December 2016 (all the subjects' history was 12 weeks). According to the principle of random control, they were divided into three experimental groups. There were 19 cases in group A (adenoidectomy under nasal endoscope after combined anesthesia), 20 cases in group B (oral montelukast sodium for nasal use of amethasone furoate) and 20 cases in group C (single oral drug). 20 patients were treated with montelukast sodium. The duration of treatment was 3 months. The total score of questionnaire (based on improved Bitar score [1]) before and after treatment was compared between the three groups. The improvement rate of adenoid volume under electronic nasopharyngoscope was measured by chi-square test. The measurement data were expressed as mean 鹵standard deviation. T test, chi-square test and other statistical tests were performed, p0.05 was statistically significant. Results: there was no significant difference in the total score of the three groups before treatment (FV 0.511 P 0.05), but after 3 months of treatment, there was no significant difference in the total score of the three groups. There were significant differences in the total scores of respiratory related sleep disorders among the three groups (FF21.829P 0.05) compared with those in group C (P 0.017). The improvement rate of adenoid volume in group A was better than that in group B (P 0.017), and the difference in total score between group B and group C was significant (P < 0.05). The difference was statistically significant (蠂 2, 6.465, P 0.017). The improvement rate of adenoid volume in group B was better than that in group C. Conclusion: the moderate and high adenoid hypertrophy associated with apnea associated sleep disorder in surgical treatment and drug therapy can alleviate the clinical symptoms and eliminate the adverse signs in children with diseases. Surgical treatment is the most effective, combined drug therapy is better than the single drug treatment. For the sick children who refuse early surgical intervention, priority should be given to the combination of medication and conservative treatment for 3 months. If the treatment is ineffective or symptomatic exacerbation, it is still recommended to receive surgical treatment as early as possible.
【學位授予單位】：蚌埠醫(yī)學院
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R766.9
【參考文獻】
相關(guān)期刊論文 前10條
1 俞晨藝;王淼;倪麗艷;;不伴鼻疾病的兒童阻塞性睡眠呼吸暫停低通氣綜合征治療方法探討[J];兒科藥學雜志;2016年09期
2 李華斌;馮韶燕;程嵐;;嗜酸粒細胞性慢性鼻竇炎的臨床特點和治療策略[J];臨床耳鼻咽喉頭頸外科雜志;2016年03期
3 葉林華;黃路圣;黃云;肖飛;徐進;;孟魯司特聯(lián)合糠酸莫米松鼻噴霧劑治療小兒腺樣體肥大臨床療效[J];兒科藥學雜志;2015年10期
4 段漢忠;夏力;盧智慧;林永東;;鼻用糖皮質(zhì)激素在腺樣體肥大性小兒鼾癥中的應用[J];中國臨床藥理學與治療學;2015年09期
5 匡慶貴;付印強;文運衡;朱莉莉;胡丹;;孟魯司特輔助治療兒童哮喘的臨床療效觀察[J];安徽醫(yī)藥;2015年04期
6 顧美珍;李曉艷;;鼻用糠酸莫米松治療兒童OSAHS的臨床療效觀察[J];同濟大學學報(醫(yī)學版);2015年02期
7 韋一;王德樂;王韶鑒;曾莉;;鼻用類固醇治療兒童變應性鼻炎伴腺樣體肥大療效分析[J];山東大學耳鼻喉眼學報;2015年02期
8 方小云;景曉雅;;糠酸莫米松鼻噴劑治療非變應性鼻炎的臨床研究[J];中國基層醫(yī)藥;2015年01期
9 殷建軍;;糠酸莫米松鼻噴霧劑聯(lián)合孟魯司特治療變應性鼻炎效果觀察[J];中國藥師;2014年11期
10 鐘寶權(quán);張素俠;薛飛;郭允偉;;孟魯司特聯(lián)合鼻內(nèi)激素治療兒童腺樣體肥大的臨床觀察[J];中國實用醫(yī)藥;2014年28期
，本文編號：2281687
本文鏈接：http://sikaile.net/yixuelunwen/wuguanyixuelunwen/2281687.html
最近更新
教材專著
